Breaking

MHRA approves new biosimilar●AstraZeneca Q1 results exceed forecast●NICE updates TA guidance for oncology●Roche launches Phase III rare disease trial●FDA grants breakthrough therapy designation●UK Biobank releases genomic dataset●GSK acquires clinical-stage biotech firm●EMA recommends novel gene therapy●MHRA approves new biosimilar●AstraZeneca Q1 results exceed forecast●NICE updates TA guidance for oncology●Roche launches Phase III rare disease trial●FDA grants breakthrough therapy designation●UK Biobank releases genomic dataset●GSK acquires clinical-stage biotech firm●EMA recommends novel gene therapy●

Long COVID Treatment: Where the Science Stands

Long COVID symptoms can drag on for years. Learn what's driving them and how treatments like H.E.L.P. apheresis are being used to address the underlying causes.

Tom Okafor, Clinical Trials Correspondent|5 August 2026|5 min read

UK MHRA Agility Reform Drives Clinical Trial Innovation

The Medicines and Healthcare products Regulatory Agency (MHRA) is poised to implement the most significant overhaul of British clinical research in 20 years. Effective 28 April 2026, the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (Statutory Instrument…

Editorial·29 July 2026·6 min read

Technology

MHRA Approves Obecabtagene Autoleucel for Relapsed B-Cell Leukaemia

The MHRA has authorised obecabtagene autoleucel for relapsed B-cell leukaemia. Discover what the FELIX trial showed and what NHS access now requires.

Tom Okafor, Clinical Trials Correspondent·27 July 2026·9 min read

Regulatory

What the New UK Clinical Trials Regulations Mean for Sponsors

The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025, signed into law in April 2025 and entering into force on 28 April 2026, represent the most substantial revision to the UK clinical trial regulatory framework since the original 2004 Regulations…

Dr. Eleanor Vance, Regulatory Affairs Editor·14 July 2026·8 min read

Latest Research & Insights

Expert analysis from pharmaceutical industry leaders

View All Articles→

Research

MHRA Strengthen Valproate Restrictions for Women of Childbearing Potential

MHRA has reinforced valproate pregnancy restrictions for women of childbearing potential. Learn what the Pregnancy Prevention Programme requires of prescribers and pharmacists.

Tom Okafor, Clinical Trials Correspondent·5 August 2026·7 min read